Market Overview:
The global cholesterol-lowering drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of obesity and other lifestyle diseases, rising awareness about the benefits of cholesterol-lowering drugs, and technological advancements in drug development. The statins segment is expected to dominate the global cholesterol-lowering drugs market during the forecast period, owing to their high efficacy and wide adoption across regions. The fibrates segment is also expected to grow at a high rate during the forecast period, due to their ability to lower bad (LDL) cholesterol levels and improve heart health outcomes.
Product Definition:
Cholesterol-lowering drugs, also known as statins, are a class of drugs that reduce levels of cholesterol in the blood. Statins are used to prevent heart disease and stroke by lowering bad cholesterol and raising good cholesterol.
Statins:
Statin drugs are the most widely used class of cholesterol-lowering medications. They work by blocking some of the steps involved in the production of cholesterol. The statins market is expected to witness significant growth over the forecast period owing to increasing prevalence and incidence rates of cardiovascular diseases (CVDs) globally, which is expected to drive demand for statin drugs. Moreover, growing awareness about lifestyle disorders among people coupled with rising disposable income levels will fuel market growth during the forecast period.
Cholesterol Absorption Inhibitors:
The market for cholesterol absorption inhibitors is expected to grow at a significant rate during the forecast period. The key drivers of this market are rising prevalence of high blood cholesterol and growing geriatric population base. According to the Centers for Disease Control and Prevention (CDC), about 80% Americans have total serum lipid levels higher than 30mg/dL, which places them at risk for heart disease.
Application Insights:
The other application segment includes academic research and patient education. Increasing awareness among individuals regarding cholesterol-related diseases is expected to boost the demand for cholesterol-lowering drugs in the household sector. In addition, growing preference for oral medication over injections is likely to propel market growth during the forecast period.
Household accounted for a significant share of 42% in 2017 owing to rising awareness about controlling Cholesterol levels among both, patients & their families as well as healthcare professionals. Furthermore, increasing prevalence of diabetes mellitus across households globally is anticipated to further drive this segment over the forecast period.
In terms of revenue, hospital application dominated with a share of 29% in 2017 owing to high usage rates and number of approved products within this sector globally.
Regional Analysis:
North America dominated the global cholesterol-lowering drugs market in 2017. This can be attributed to the high prevalence of cardiovascular diseases, rising geriatric population, and availability of advanced healthcare facilities. Moreover, increasing government initiatives for promoting healthy lifestyles will boost market growth further. For instance, as per a CDC study in 2016 around 45% of adults in U.S eat five or more servings of breads and cereals daily which is a major risk factor for obesity and heart diseases (1).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to factors such as growing disposable income coupled with rise in consumer awareness regarding various treatment options available for lowering cholesterol levels (2). In addition, increase in target disease population along with rapid urbanization will drive regional product demand further driving industry dynamics towards maturity during the forecast period from 2018 to 2030 (3).
Growth Factors:
- Increasing prevalence of obesity and other lifestyle-related diseases such as diabetes, which leads to an increase in the demand for cholesterol-lowering drugs.
- Growing awareness about the benefits of cholesterol-lowering drugs among people, especially those who are at a high risk of developing heart diseases or other health complications related to high cholesterol levels.
- Technological advancements in the development of novel and more effective cholesterol-lowering drugs that can help reduce LDL (bad) cholesterol levels by a significant margin.
- The increasing number of approvals for novel lipid-modifying therapies by regulatory agencies such as the FDA and EMA is expected to fuel market growth over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cholesterol-Lowering Drugs Market Research Report
By Type
Statins, Cholesterol Absorption Inhibitors, Fibrates, PCSK9 Inhibitors
By Application
Hospital, Household, Other
By Companies
AstraZeneca, Merck, Pfizer, Kowa, Daiichi Sankyo, AbbVie, Novartis, Sanofi, Amgen, Bristol-Myers Squibb, AstraZeneca
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Cholesterol-Lowering Drugs Market Report Segments:
The global Cholesterol-Lowering Drugs market is segmented on the basis of:
Types
Statins, Cholesterol Absorption Inhibitors, Fibrates, PCSK9 Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Household, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Merck
- Pfizer
- Kowa
- Daiichi Sankyo
- AbbVie
- Novartis
- Sanofi
- Amgen
- Bristol-Myers Squibb
- AstraZeneca
Highlights of The Cholesterol-Lowering Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Statins
- Cholesterol Absorption Inhibitors
- Fibrates
- PCSK9 Inhibitors
- By Application:
- Hospital
- Household
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cholesterol-Lowering Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cholesterol-lowering drugs are medications that help to lower the levels of cholesterol in the blood.
Some of the major companies in the cholesterol-lowering drugs market are AstraZeneca, Merck, Pfizer, Kowa, Daiichi Sankyo, AbbVie, Novartis, Sanofi, Amgen, Bristol-Myers Squibb, AstraZeneca.
The cholesterol-lowering drugs market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cholesterol-Lowering Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cholesterol-Lowering Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cholesterol-Lowering Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cholesterol-Lowering Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cholesterol-Lowering Drugs Market Size & Forecast, 2018-2028
4.5.1 Cholesterol-Lowering Drugs Market Size and Y-o-Y Growth
4.5.2 Cholesterol-Lowering Drugs Market Absolute $ Opportunity
Chapter 5 Global Cholesterol-Lowering Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cholesterol-Lowering Drugs Market Size Forecast by Type
5.2.1 Statins
5.2.2 Cholesterol Absorption Inhibitors
5.2.3 Fibrates
5.2.4 PCSK9 Inhibitors
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cholesterol-Lowering Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cholesterol-Lowering Drugs Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Household
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cholesterol-Lowering Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cholesterol-Lowering Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cholesterol-Lowering Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Cholesterol-Lowering Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cholesterol-Lowering Drugs Market Size Forecast by Type
9.6.1 Statins
9.6.2 Cholesterol Absorption Inhibitors
9.6.3 Fibrates
9.6.4 PCSK9 Inhibitors
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cholesterol-Lowering Drugs Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Household
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cholesterol-Lowering Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Cholesterol-Lowering Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cholesterol-Lowering Drugs Market Size Forecast by Type
10.6.1 Statins
10.6.2 Cholesterol Absorption Inhibitors
10.6.3 Fibrates
10.6.4 PCSK9 Inhibitors
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cholesterol-Lowering Drugs Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Household
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cholesterol-Lowering Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cholesterol-Lowering Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cholesterol-Lowering Drugs Market Size Forecast by Type
11.6.1 Statins
11.6.2 Cholesterol Absorption Inhibitors
11.6.3 Fibrates
11.6.4 PCSK9 Inhibitors
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cholesterol-Lowering Drugs Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Household
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cholesterol-Lowering Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Cholesterol-Lowering Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cholesterol-Lowering Drugs Market Size Forecast by Type
12.6.1 Statins
12.6.2 Cholesterol Absorption Inhibitors
12.6.3 Fibrates
12.6.4 PCSK9 Inhibitors
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cholesterol-Lowering Drugs Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Household
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cholesterol-Lowering Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cholesterol-Lowering Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cholesterol-Lowering Drugs Market Size Forecast by Type
13.6.1 Statins
13.6.2 Cholesterol Absorption Inhibitors
13.6.3 Fibrates
13.6.4 PCSK9 Inhibitors
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cholesterol-Lowering Drugs Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Household
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cholesterol-Lowering Drugs Market: Competitive Dashboard
14.2 Global Cholesterol-Lowering Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Merck
14.3.3 Pfizer
14.3.4 Kowa
14.3.5 Daiichi Sankyo
14.3.6 AbbVie
14.3.7 Novartis
14.3.8 Sanofi
14.3.9 Amgen
14.3.10 Bristol-Myers Squibb
14.3.11 AstraZeneca
